Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

[1]  P. Kantoff,et al.  Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. , 2019, European urology.

[2]  A. Wyatt,et al.  A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). , 2018, Annals of Oncology.

[3]  A. Fourrier-Réglat,et al.  Effectiveness of Cetuximab as First‐Line Therapy for Patients With Wild‐Type KRAS and Unresectable Metastatic Colorectal Cancer in Real‐Life Practice: Results of the EREBUS Cohort , 2018, Clinical colorectal cancer.

[4]  O. Caffo,et al.  Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. , 2018, Future oncology.

[5]  J. Carles,et al.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  O. Sartor,et al.  Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature , 2017, Current medical research and opinion.

[7]  C. Sternberg,et al.  Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. , 2016, Critical reviews in oncology/hematology.

[8]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[9]  J. Benichou,et al.  Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort , 2014, Targeted Oncology.

[10]  B. Escudier,et al.  Who dies from prostate cancer? , 2014, Prostate Cancer and Prostatic Disease.

[11]  S. Park,et al.  Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program , 2014, Cancer Chemotherapy and Pharmacology.

[12]  E. Esteban,et al.  Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program , 2014, Expert opinion on drug safety.

[13]  P. Marchetti,et al.  Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. , 2014, Future oncology.

[14]  A. Fourrier-Réglat,et al.  Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study , 2014, Leukemia & lymphoma.

[15]  S. Fosså,et al.  Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. , 2014, European journal of cancer.

[16]  W. Oh,et al.  The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer , 2014, Therapeutic advances in urology.

[17]  H. Gelderblom,et al.  Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands. , 2013, Clinical genitourinary cancer.

[18]  P. Albers,et al.  Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. , 2013, European urology.

[19]  B. Tombal,et al.  Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[21]  S. Fosså,et al.  106 Cabazitaxel adverse events are manageable in senior adults with metastatic castration-resistant prostate cancer (mCRPC): Results of the European Compassionate Use Programme , 2013 .

[22]  A. Fourrier-Réglat,et al.  Chemotherapy and targeted agents for colorectal cancer in a real‐life setting anticipate guidelines: the COLCHIC cohort study , 2013, Fundamental & clinical pharmacology.

[23]  S. Oudard.  TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. , 2011, Future oncology.

[24]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[25]  X. Rébillard,et al.  Le cancer de la prostate en France en 2001 : état des pratiques et facteurs associés à la réalisation d’une prostatectomie totale , 2009 .

[26]  J. Benichou,et al.  Impact of Prescriber Nonresponse on Patient Representativeness , 2008, Epidemiology.

[27]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[28]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[29]  R. C. Macridis.  A review , 1963 .

[30]  A. Guizard,et al.  [Prostate cancer management and factors associated with radical prostatectomy in France in 2001]. , 2009, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[31]  S. Gabriel,et al.  Systematic Review of the Literature , 2021, Adherence to Antiretroviral Therapy among Perinatal Women in Guyana.

[32]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.